J&J beats forecast, takes new charge for recalled hips
Jan 22 (Reuters) - Johnson & Johnson reported better-than-expected fourth-quarter earnings on Tuesday, fueled by rebounding sales of prescription drugs and demand for its medical devices, but took another big special charge for its recalled artificial hips.
The diversified healthcare company on Tuesday said it earned $2.6 billion, or 91 cents per share. That compared with $218 million, or 8 cents per share, in the year-ago period when the company took charges of more than $3 billion, including $800 million for medical costs related to recalls of defective "metal-on-metal" hip replacement devices made by its DePuy Orthopedics unit.
Excluding special items, J&J earned $1.19 per share. Analysts, on average, expected $1.17 per share.
Global revenue rose 8 percent to $17.56 billion, below Wall Street expectations of $17.7 billion.
- Radar showed missing plane may have turned back: Malaysia military
- Exclusive: Malaysia plane probe narrows on mid-air disintegration - source
- Missing Malaysian jet may have disintegrated in mid-air: source |
- Malaysian plane presumed crashed; questions over false IDs |
- Merkel raps Putin as Russian forces tighten grip on Crimea |